Higher SARS-COV-2 spike antibody levels are associated with reduced risk of subsequent symptomatic and severe COVID-19.
Jin, Yue; Yang, Fei; Rank, Christopher; Letovsky, Stanley; Ramge, Peter and Jochum, Simon from Roche Information Solutions, Roche Diagnostics GmbH, Roche Diagnostics Solutions, and Roche Diagnostics International presented a poster during ISPOR 2024.
The objective was to assess the association between SARS-CoV-2 S antibody levels and risk of COVID-19 related outcomes (symptomatic and severe infections). Roche Diagnostics used two real-world-date sets, Labcorp and PurpleLab, and linked the two through data tokenization. Antibody data from the ACOV2S assay, obtained from routine clinical testing by Labcorp laboratories in the US between 4/1/2021 and 6/30/2022, is combined with the infection and vaccination records of the same subjects captured from the PurpleLab Open and Closed claims repository.
The insights pulled from this study done by Roche Diagnostics can lead to a better understanding of the associations between natural immunity and vaccines on the quantitative level of antibodies which may, in turn, inform future public health recommendations.
